drug integrity News
-
Sygnature Discovery to Deploy Iktos’s AI for Drug Design Software Makya
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design and Sygnature Discovery, a leading integrated drug discovery CRO headquartered in Nottingham, UK, with expertise across a range of therapeutic and biological target classes today announced a collaboration agreement in AI for new drug design. Under the 3-year agreement, Sygnature will deploy Iktos’ de novo ...
By Iktos
-
Creative Biostructure Drug Discovery Established MagHelixTM CADD Platform
Creative Biostructure Drug Discovery, a sub-brand of Creative Biostructure, whose mission is to accelerate the preclinical development of innovative drugs through structural insight, recently established a MagHelix™ CADD Platform, a comprehensive platform for new drug discovery that integrates a variety of computer applications. Computer-aided drug design (CADD) has penetrated into all ...
-
Lyra Therapeutics To Present Lantern Phase 2 Study Results For Lyr 210 In Oral Presentation At Cosm 2021 Virtual
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that the company will present Phase 2 results from the LANTERN study for LYR-210, the company’s lead product candidate ...
-
endpoint and McCreadie Group Software Integration Reduces Drug Speed to Market and Streamlines Research Pharmacy Workflows
endpoint Clinical, the leading global interactive response technology (IRT®) company, and McCreadie Group, the market leader in automating manual processes in Investigational Drug Services (IDS), have collaborated to increase study product accountability transparency for study sponsors, reduce site burdens associated with clinical study IMP management, and improve related data integrity via ...
-
Lonza to Establish Drug Product Manufacturing Services in Guangzhou, China
As part of Lonza's continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services The introduction of drug product manufacturing ...
-
Lonza to Establish Drug Product Manufacturing Services in Guangzhou, China
As part of Lonza's continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services The introduction of drug product manufacturing ...
-
SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS Test at 2021 ASCO Annual Meeting
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today announced that new data from a study summarizing the predictive value of the PARIS® Test across solid tumor cancers will be presented during a poster session (abstract number 2602) at the American ...
-
Lyra Therapeutics Provides Corporate Update and Anticipated Milestones for 2021
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today provided a corporate update and anticipated milestones for 2021. Corporate Update & Anticipated Milestones for 2021 LYR-210: ...
-
SilcsBio and Helix BioStructures Launch Partnership to Collaborate in Fueling Pharmaceutical Drug Design Opportunities
August 29, 2022, Baltimore, MD and Indianapolis, IN – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, today announced the launch of a partnership with Helix BioStructures, a pharmaceutical-biotech contract research organization that provides high-quality, integrated drug discovery services to the pharmaceutical community in the ...
-
CD BioSciences Introduces New GPCR Purification Service for GPCR Research and Drug Development
CD BioSciences, a leading customer-focused biotechnology company based in New York, introduces new GPCR purification services to support and facilitate GPCR research and drug development. CD BioSciences has built an unparalleled GPCR purification platform to provide the most reliable service for researchers. With more than 800 members, G protein-coupled receptors (GPCRs) constitute the largest ...
-
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
Plan ensures shareholders are protected and treated equitably Does not prevent the Zymeworks Board from engaging on future acquisition proposal that is in the best interests of all shareholders VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Jun. 10, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional ...
-
SEngine Precision Medicine Announces New Collaboration to Bring PARIS Test to Patients with CNS Cancers
SEATTLE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine and Dana-Farber Cancer Institute today announced a collaboration to bring SEngine’s PARIS® Test to adult and pediatric patients with primary or metastatic solid-tumor central nervous system (CNS) cancers. The collaboration aims to provide patients and their oncologists with more information as to what therapies could ...
-
CD Formulation Newly Launches Drug Packaging Services for the Pharmaceutical Industry
Packaging is another factor that decides the stability and integrity of drugs. Except for the role as an excipient producer and supplier, the US-based CRO company CD Formulation today announces that it newly launches a wide range of pharmaceutical packaging services, providing support throughout the whole process of packaging design, from material selection to chemical and surface analysis and to ...
-
CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI
CD ComputaBio, a reputable computational service provider in the field of biology, has proudly announced the launch of its Antibody De Novo Design technology, marking a pivotal moment in the field of drug discovery and development. This service harnesses the power of AI to engineer antibodies with unmatched precision, paving the way for targeted therapies, personalized medicine, and cutting-edge ...
-
SEngine Precision Medicine closes Series A bringing total financing to $19M enabling continued advancement of personalized cancer treatments
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform that matches cancer patients to the right drug and also drives drug discovery. The Series A2 round was led by the Washington Research Foundation along with ...
-
Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets
Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc (“Valo”) have launched LogicaTM, an artificial intelligence (AI) powered drug solution that directly translates clients’ biological insights into optimized preclinical assets. Logica leverages Valo’s AI-powered Opal Computational Platform and Charles River’s leading preclinical expertise, ...
-
Healx appoints ex-Dyson lead, Andrew Watson, as VP of Artificial Intelligence
Experienced machine learning and engineering leader Andrew Watson joins Healx from technology giant Dyson as VP of Artificial Intelligence. In his new role, Andrew will deepen the investment in Healx’s artificial intelligence team and scale Healx’s technical capabilities in order to identify and progress more novel treatments for rare diseases. Andrew’s appointment reinforces ...
By Healx Ltd.
-
Lyra Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. Key Fourth ...
-
PARIS Test Identified Effective Therapy for Patient with Terminal Ovarian Cancer
SEATTLE, Sept. 13, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine announces dramatic results for a 52-year-old patient with terminal ovarian cancer who received the PARIS® Test in early summer 2020. An interim case summary was included in SEngine’s poster presentation at the AACR 2021 annual meeting. The patient’s oncologist, Heidi Gray, MD, who specializes in ovarian cancer ...
-
Thermo Fisher Scientific to Acquire PPD, Inc., a Leading Clinical Research Organization
Establishes Thermo Fisher as a global leader in the attractive and high growth clinical research services industry Adds highly complementary services for the company's fastest growing end market Offers both meaningful cost and revenue synergies which will further accelerate growth Expected to be immediately and significantly accretive to Adjusted Earnings Per Share (EPS)¹ after close ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you